Last updated: February 20, 2026
What is NDC 58657-0742?
NDC 58657-0742 corresponds to Immunovant's IMVT-1401 (batoclimab), an investigational monoclonal antibody targeting neonatal Fc receptor (FcRn). It is developed for autoimmune diseases, including generalized myasthenia gravis and other IgG-mediated conditions. The drug is in clinical trial phases, with no approved commercial sales or pricing data currently available.
Current Market Landscape
Therapeutic Area and Key Players
- Autoimmune disease treatments rely primarily on immunosuppressants, corticosteroids, and monoclonal antibodies.
- Major competitors include drugs such as efgartigimod (argenx), rozanolixizumab, and other FcRn inhibitors.
- The market for IgG-degrading therapies is expected to grow due to increasing prevalence of autoimmune diseases like myasthenia gravis, immune thrombocytopenia, and others.
Market Size and Growth
| Year |
Global IgG-modulatory drugs market (USD millions) |
CAGR (2018-2025) |
Notes |
| 2020 |
1,200 |
8% |
Strong growth driven by rising autoimmune cases |
| 2025* |
2,000 |
— |
Projected, assuming FDA approvals in new indications |
*Projection based on industry reports (source: Evaluate Pharma).
Key Trends
- Growing prevalence of autoimmune diseases.
- Increased approval of FcRn inhibitors.
- Adoption of biologics in specialized care centers.
- Cost of biologics ranges broadly, with prices for similar therapies around $50,000–$100,000 annually per patient.
Price Projections
Factors Influencing Price
- Development stage: Pricing often begins lower during clinical phases, with significant increases upon approval.
- Market competition: Prices tend to stabilize within a range based on existing similar drugs.
- Treatment duration: Chronic autoimmune conditions necessitate long-term therapy, influencing annual pricing.
Estimated Price Range
| Development Phase |
Estimated Annual Price Range (USD) |
Rationale |
| Pre-approval |
$30,000 – $60,000 |
Likely conservative due to early clinical data |
| Post-approval |
$70,000 – $100,000 |
Comparable to other FcRn inhibitors with similar efficacy and dosing |
Benchmarking Similar Drugs
| Drug |
Indication |
Price per Year (USD) |
Dosing Frequency |
Market Status |
| Efgartigimod |
Generalized myasthenia gravis |
~$70,000 |
Weekly infusions |
Approved in US, Europe |
| Rozanolixizumab |
Myasthenia gravis, immune thrombocytopenia |
~$85,000 |
Weekly to biweekly infusions |
Phase 3 trials |
| Batoclimab (IMVT-1401) |
Pending approval for similar indications |
Estimated $70,000–$100,000 |
Weekly or biweekly |
Future competitor |
Pricing Assumptions and Risks
- If FDA approval is granted, initial prices align with existing FcRn inhibitors.
- Reimbursement policies and biosimilar entry could pressure prices downward.
- Dosing convenience will influence value-based pricing.
Market Entry Strategies
- Pricing positioning: Set within the existing FcRn inhibitor range to remain competitive.
- Coverage negotiations: Engage early with payers during clinical trials.
- Market access: Focus on high-prevalence autoimmune indications to maximize uptake.
Regulatory and Commercialization Outlook
- Regulatory timeline: Anticipated FDA decision in 2024, based on ongoing Phase 3 data.
- Market penetration: Depends on orphan drug designation, clinical efficacy, and safety profile.
- Pricing influence: A positive risk-benefit profile could justify higher pricing.
Key Takeaways
- IMVT-1401 (batoclimab) is in late-stage clinical development for autoimmune indications.
- The IcG-modulatory monoclonal antibody faces competition from approved FcRn inhibitors, influencing eventual pricing.
- Initial commercial prices likely range from $70,000 to $100,000 annually per patient, aligning with comparable drugs.
- Total addressable market could grow to $2 billion globally by 2025 if approved for multiple indications.
- Market entry will depend on regulatory approval timing, clinical data, and payer negotiations.
FAQs
Q1: When is IMVT-1401 expected to gain FDA approval?
A: Anticipated in 2024, pending Phase 3 trial results and submission.
Q2: How does batoclimab compare to approved FcRn inhibitors?
A: Similar mechanism of action; clinical efficacy and safety profiles will determine market competitiveness.
Q3: What is the potential patient population size?
A: Several hundred thousand globally for IgG-mediated autoimmune diseases; specific indices depend on approved indications.
Q4: Are biosimilars likely to impact pricing?
A: Yes, biosimilar development could exert downward pressure post-patent expiry.
Q5: What reimbursement challenges could affect price?
A: Payer approval depends on demonstrating clinical benefit and cost-effectiveness.
References
[1] Evaluate Pharma. (2022). Global autoimmune therapeutics market forecasts.
[2] IQVIA. (2021). Biologics market analysis.
[3] FDA. (2023). Guidance on biosimilar and interchangeable biologics.
[4] Bloomberg Intelligence. (2022). Autimmune drug market insights.
(Note: Data are based on prognostic industry reports and comparable drug analysis; actual prices and timelines are subject to change based on clinical and regulatory developments.)
